An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
Dompé Farmaceutici S.p.A · NCT07395232
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 10–65 · All sexes
- Healthy volunteers
- Not accepted (a condition is required)
- Study type
- Interventional · Phase 3
- Target enrollment
- 153
- US sites recruiting
- 8
- Study start
- December 1, 2025
- Record last updated
- September 21, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC. The study consists of 2 cohorts: the adult cohort includes approximately 138 participants and the pediatric cohort which includes approximately 15 participants. The cohorts will be randomized separately. Adult participants will be randomized in a 1:1 ratio, while pediatric participants will be randomized in a 2:1 ratio to receive DFL24498 or vehicle.
Being studied: DFL24498; Vehicle; dexamethasone sodium phosphate (DSP) ophthalmic solution
Conditions: Atopic Keratoconjunctivitis
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply:
- Male or Female aged ≥ 10 and ≤ 65 years.
- Diagnosis of AKC in both eyes, including the presence or medical history of the following:
- other atopic condition (ie., atopic dermatitis, periocular eczema, asthma, allergic rhinitis), AND
- chronic allergic blepharoconjunctivitis and/or keratoconjunctivitis.
- Ocular itching of at least 50 as assessed by VAS scale.
- Corneal fluorescein staining assessed by modified Oxford scale of at least grade 1 AND a bulbar conjunctival hyperemia assessed by VBR 10 scale of at least 40 (range 0 to 100) in the same eye.
- A composite symptoms score (CSyS) ≥ 5 (sum of the severity scores graded 0 to 3 for each of the following: itching, tearing, ocular discomfort, photophobia, and mucous discharge score) (CSyS range of 0 to 15).
- If a woman of childbearing potential (WOCBP), must have a negative pregnancy test at both screening and baseline visit, and use an acceptable contraception method.
Exclusion Criteria
Participants will be excluded if any of the following criteria apply:
- Inability to speak and understand the local language sufficiently to understand the nature of the study, to provide written informed consent, and to allow the completion of all study assessments.
- Evidence of an active ocular infection in either eye.
- Intraocular inflammation defined as anterior chamber flare > 0 by Standardization of Uveitis Nomenclature (SUN) grading, in either eye.
- Known or suspected ocular malignancy (ocular surface, intraocular, ocular adnexa).
- Presence of cancer or any other systemic or unstable disease that may affect the ability to participate in the clinical study in the opinion of the investigator including basal cell carcinoma.
- Participants that are anatomically monocular.
- Systemic disease not stabilized within 1 month before the screening visit (eg, diabetes with glycemia out of range, thyroid malfunction) or judged by the investigator to be incompatible with the study (eg, current systemic infections) or with a condition incompatible with the frequent assessment required by the study.
Note: Additional protocol defined Inclusion/Exclusion criteria apply
Recruiting US locations
Bowden Eye Associates - Southside Location
Jacksonville, FL 32256
University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute
Miami, FL 33136
Clayton Eye Clinical Research
Morrow, GA 30260
Ophthalmology Associates
St Louis, MO 63131
NYU Langone Health - Eye Center
New York, NY 10017
Duke Eye Center - Ophthalmology
Durham, NC 27710
Total Eye Care, PA
Memphis, TN 38119
Baylor University Jamail Specialty Care Center- Alkek Eye Center- Ophthalmology
Houston, TX 77030
Study contacts (from the official record)
- Dompé farmaceutici S.p.A. Via Santa Lucia, 6, 20122 Milan (MI) · +39 02 583 831